

Contact Dermatitis (Dermatology) - Drugs In Development, 2021

<https://marketpublishers.com/r/C61E975E92F9EN.html>

Date: July 2021

Pages: 50

Price: US\$ 2,000.00 (Single User License)

ID: C61E975E92F9EN

Abstracts

Contact Dermatitis (Dermatology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Drugs In Development, 2021, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.

Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development

history and latest news and press releases.

The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 3 respectively. Similarly, the Universities portfolio in Phase III stages comprises 1 molecules, respectively.

Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Contact Dermatitis

(Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Contact Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Contact Dermatitis - Overview
- Contact Dermatitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Contact Dermatitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Contact Dermatitis - Companies Involved in Therapeutics Development
- Aposcience AG
- Edesa Biotech Inc
- Hapten Sciences Inc
- ILiAD Biotechnologies LLC
- Signum Dermalogix Inc
- Contact Dermatitis - Drug Profiles
- APO-2 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- diflucortolone - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EB-01 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EB-05 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

HPT-721 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis [strain BPZE1] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIG-1322 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Contact Dermatitis - Dormant Projects

Contact Dermatitis - Discontinued Products

Contact Dermatitis - Product Development Milestones

Featured News & Press Releases

Mar 09, 2021: Edesa Biotech completes enrollment for interim clinical study milestone

Nov 03, 2020: Edesa Biotech achieves enrollment milestone in dermatitis study

May 15, 2020: Contact dermatitis: potential new treatments with biologic drug

Dec 03, 2019: Edesa Biotech reports positive healthy volunteer data and expands Phase 2b Dermatitis Study to patients with Facial Lesions

Oct 21, 2019: Edesa Biotech enrolls first patient in phase 2b dermatitis study

Jul 25, 2019: Edesa Biotech completes manufacturing for upcoming dermatitis study

Jun 20, 2019: Edesa Biotech receives approval to proceed with U.S. clinical study

Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Contact Dermatitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Contact Dermatitis - Pipeline by Aposcience AG, 2021
Contact Dermatitis - Pipeline by Edesa Biotech Inc, 2021
Contact Dermatitis - Pipeline by Hapten Sciences Inc, 2021
Contact Dermatitis - Pipeline by ILiAD Biotechnologies LLC, 2021
Contact Dermatitis - Pipeline by Signum Dermalogix Inc, 2021
Contact Dermatitis - Dormant Projects, 2021
Contact Dermatitis - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Contact Dermatitis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Contact Dermatitis (Dermatology) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/C61E975E92F9EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C61E975E92F9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970